LKT Labs

Biochemicals for Life Science Research

Linagliptin

Product ID L337521
Cas No. 668270-12-0
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $41.00 In stock
10 mg $54.50 In stock
25 mg $95.50 In stock
50 mg $163.50 In stock
Bulk Quote

Quicklinks

Description

Linagliptin is a dipeptidyl peptidase 4 inhibitor glucose-lowering compound with low risk of inducing hypoglycaemia. It has been found that linagliptin may modify several measures of microvascular function including hyperaemia area, resting blood flow, and peak blood flow in the fasting state. Treatment of STZ-diabetic Wistar rats was shown to decreases levels of oxidative stress, protect against microvascular damage, enhance neuronal cell survival, and prevent vasoregression.
Furthermore, treatment was found to decrease aortic pulse wave velocity, glycated haemoglobin, fasting plasma glucose, and triglycerides in people with early type 2 diabetes. Contrarily, linagliptin has also been known to cause adverse reactions such as ulcers and blisters.

Product Info

Cas No.

668270-12-0
Purity

≥98%
Formula

C25H28N8O2
Formula Wt.

472.55
Chemical Name

8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
IUPAC Name

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Synonym

Tradjenta, BI 1356, Ondero
Solubility

Soluble in DMSO (17 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (1 mg/ml at 25 °C), 0.5% hyroxyethylcellulose (30 mg/ml at 25 °C), and methanol.

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

L337521 MSDS PDF
Info Sheet

L337521 Info Sheet PDF

References

Jax T, Stirban A, Terjung A, et al. A randomized, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. PMID: 28109295.

Dietrich N, Kolibabka M, Busch S, et al. The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. PLoS One. 2016 Dec 12;11(12):e0167853. PMID: 27942008.

de Boer SA, Heerspink HJL, Juarez Orozco LE, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab. 2017 Aug;19(8):1147-1154. PMID: 28244635.

Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. BMJ Case Rep. 2017 May 31;2017. PMID: 28566414.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.